GEN Exclusives

More »

GEN News Highlights

More »
Aug 20, 2014

TB Alliance Picks Up Novartis' Tuberculosis-Fighting Compounds

  • Novartis inked an agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds designed to tackle tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD). NITD will transfer its TB R&D program to TB Alliance, which will take financial and operational responsibility for continued research, development, approval, and distribution of compounds in the portfolio.

    Among the compounds TB Alliance is picking up are indolcarboxamides, a class of drugs that are active against drug-sensitive and multiresistant strains of the infectious lung disease. One of these preclinical compounds, NITD304, can reportedly block MmpL3, a protein essential for the TB bacterium's survival.

    "Our long-standing partnership with Novartis gives us confidence in the scientific underpinnings of the TB portfolio," Mel Spigelman, M.D., TB Alliance's president and CEO, said in a statement. "We look forward to advancing the most promising compounds into the clinic to meet the urgent need for new TB treatments."

    Novartis and TB Alliance have been working together for some time, including a partnership made in 2004 between TB Alliance and NITD aimed at identifying lead compounds in the nitroimidazopyran class for the treatment of TB.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »